Biden signs new executive order to expand US bio-manufacturing, some US media interpret "targeting China"

　　[Global Web Report] According to the ABC report, US President Biden signed an executive order on the 12th local time to encourage US biotechnology production and research.

The order is aimed at promoting U.S. manufacturing in the pharmaceutical industry, as well as in industries such as agriculture, plastics and energy, the report said.

Biden himself emphasized the importance of "fighting cancer" in his speech that day.

Previously, US media broke the news that after the "chip bill", Biden is preparing to sign an executive order to help expand bio-manufacturing in the United States, and the target is allegedly still "targeting China."

When the "Voice of America" ​​and other media reported that Biden signed the executive order, it also interpreted that the move was "response to China's challenges in biotechnology."

　　According to ABC, it cited a White House report that on Wednesday (14th), the Biden administration will host a meeting to announce new investments by several federal agencies.

A senior administration official would not say how much funding would be announced on Wednesday, the report said.

　　The ABC quoted an anonymous official who was not authorized to speak publicly as saying that the White House wants to support the production of biotech products developed in the United States, rather than having innovative American products produced abroad.

The official also claimed that the administration's goal is to expand U.S. biomanufacturing capabilities and that other countries, especially China, have been actively investing in the industry, posing risks to U.S. leadership and competitiveness.

The ABC also referred to Biden's signing of the "Chip and Science Act" last month, saying the bill was designed to reduce the U.S. economy's reliance on semiconductors produced overseas.

　　"Voice of America" ​​said on the 12th that Biden's latest executive order is considered to be a supplement to the "Chip and Science Act" signed by Biden last month.

The White House said, "The bioeconomy remains America's strength and a huge opportunity." If the full potential of biotechnology and biomanufacturing can be harnessed, "we will be able to ... make almost anything we use in our daily lives, medicines, fuels, plastics, and more, and continue to drive America’s growth.”

　　U.S. media has previously revealed that, following the "Chip Act", U.S. President Biden is preparing to sign an executive order to help expand bio-manufacturing in the United States, and the target is allegedly still "targeting China."

Bloomberg reported on the 10th that U.S. national security and intelligence officials are "particularly concerned about the reliance on China's advanced biomanufacturing infrastructure."

In the past 20 years, with the refinement of the global division of labor, many pharmaceutical manufacturing, including drugs for treating hypertension and diabetes, and antibiotics, has been transferred from the United States, Europe and Japan to China.

Some American medical experts worry that "the United States' dependence on Chinese medicines is a big problem."

But some analysts believe that, in fact, the United States has one of the most powerful biotechnology industries in the world, and leads in research and development.

However, the number of innovative biopharmaceuticals in China is still very low and will not pose a threat to the global position of the United States in the short term.